Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023 07:30 ET
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
Avricore Health Corporate Update – Company Demonstrates Strong Growth
November 30, 2023 12:58 ET
|
Avricore Health Inc.
Avricore Health provides a corporate update and results for the first 9 months of 2023.
HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion
August 08, 2023 11:54 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a reseller...
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
June 26, 2023 07:45 ET
|
POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...
Avricore Health Hosts 2023 Annual General Meeting and Welcomes New Board Members
June 21, 2023 18:38 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, June 21, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) held its annual general meeting to elect directors, appoint its auditor and...
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
May 25, 2023 08:30 ET
|
POINT Biopharma
PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
May 15, 2023 07:35 ET
|
POINT Biopharma
INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...
Avricore Health Corporate Updates on Audited Results for 2022
May 02, 2023 07:30 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today is pleased to announce its audited final results for 2022. ...
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
March 27, 2023 08:00 ET
|
POINT Biopharma
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH...
Avricore Health Corporate Update – Earnings Advisory 2022 and 2023 Objectives
February 01, 2023 08:00 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is entering the second year of a multi-year growth plan to bring HealthTab,...